WHO ICTRP trial
Phase IIa study to evaluate the efficacy of the ISTH0036 in treatment naive and…
CTRI/2022/04/041823 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2022/04/041823 |
|---|---|
| Public title | Phase IIa study to evaluate the efficacy of the ISTH0036 in treatment naive and previously treated patients with Macular Degeneration and Diabetic Macular Edema |
| Scientific title | TGF-BETa 2 antisense ISTH0036 for the Treatment of diabetic macular Edema (DME) and neovascular age-related maculaR degeneration (nAMD) as Monotherapy or in combination with Aflibercept The ââ?¬Å?BETTERââ?¬? Study |
| Primary sponsor | Isarna Therapeutics |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | India |
| Conditions | Health Condition 1: E133- Other specified diabetes mellituswith ophthalmic complications |
| Interventions | Intervention1: ISTH0036: The duration of study participation is 9 months preceded by an up to 40 days screening period. Screening and Baseline Visit may be combined. Last treatment is at month 6 and the Primary Endpoint will be assessed at… |
| Registration date | Dec 4, 2022 |
| Target size | 48 |
| Secondary IDs | ISTH-02-211, Version 2.1, 20 Apr 2022 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: